GlassScriptPhysician profile
Mark F Lierz
NPI 1497856702
$5,538.87
in general payments reported to CMS, 2019-2025
48 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $553 · 2021: $1,206 · 2022: $949 · 2023: $575 · 2024: $548 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $982.68 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Abbvie INC. | $917.17 | 2019-2025 | |
| Pfizer INC. | $398.83 | 2019-2025 | |
| Janssen Biotech, INC. | $392.65 | 2020-2025 | Erleada, Akeega |
| Caldera Medical, INC | $288.21 | 2022 | |
| Boston Scientific Corporation | $232.19 | 2019-2023 | Spaceoar Vue System - 10ml |
| Olympus America INC. | $194.43 | 2019-2025 | Itind System, Soltive |
| Allergan, INC. | $157.60 | 2019-2022 | |
| Medtronic, INC. | $143.66 | 2021-2024 | Interstim |
| Amgen INC. | $134.38 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $130.02 | 2019-2020 | |
| Coloplast Corp | $128.87 | 2021-2025 | Porges Coloplast |
| Novartis Pharmaceuticals Corporation | $123.80 | 2020-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $78.63 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lierz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.